Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tempers Flare At ODAC Meeting, And Pazdur Must Call "Order In The Court"

Executive Summary

Tempers frayed as the FDA Oncologic Drugs Advisory Committee gathered to review GlaxoSmithKline's Avodart (dutasteride) and Merck's Proscar (finasteride) for prostate cancer prevention Dec. 1.

You may also be interested in...



From Avastin To Zevalin: ODAC’s Most Memorable Moments

The current and former leaders of FDA’s Oncologic Drugs Advisory Committee recount their most memorable moments of service on the panel.

Prostate Cancer Prevention Endpoint May Have Been Key Problem As ODAC Votes Down BPH sNDAs

The problems that GlaxoSmithKline and Merck had in trying to convince FDA's Oncologic Drugs Advisory Committee to add labeling on prostate cancer risk reduction to Avodart (dutasteride) and Proscar (finasteride) may have been avoided had the firms selected a stronger mortality endpoint for their trials.

Prostate Cancer Prevention Endpoint May Have Been Key Problem As ODAC Votes Down BPH sNDAs

The problems that GlaxoSmithKline and Merck had in trying to convince FDA's Oncologic Drugs Advisory Committee to add labeling on prostate cancer risk reduction to Avodart (dutasteride) and Proscar (finasteride) may have been avoided had the firms selected a stronger mortality endpoint for their trials.

Topics

UsernamePublicRestriction

Register

PS052918

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel